Case Report: Combination of Omalizumab and Dupilumab for Recalcitrant Bullous Pemphigoid

E-resources

PDF

Peer reviewed Open access

Case Report: Combination of Omalizumab and Dupilumab for Recalcitrant Bullous Pemphigoid

Seyed Jafari, S Morteza; Feldmeyer, Laurence; Bossart, Simon; Simon, Dagmar; Schlapbach, Christoph; Borradori, Luca

Frontiers in immunology, 01/2021, Volume: 11

Journal Article

Bullous pemphigoid (BP) is a blistering autoimmune skin disease. Omalizumab, a monoclonal antibody directed to IgE, showed a beneficial effect in treatment of recalcitrant BP in case series. More recently, dupilumab, an interleukin (IL)-4-receptor alpha antagonist, also showed promising preliminary results. We describe a patient with refractory BP who showed a complete response to a combination therapy with omalizumab and dupilumab.

Keep searching

Author

Access to the JCR database is permitted only to users from Slovenia. Your current IP address is not on the list of IP addresses with access permission, and authentication with the relevant AAI accout is required.

Year	Impact factor		Edition		Category		Classification
Year	JCR	SNIP	JCR	SNIP	JCR	SNIP	JCR	SNIP

Links to authors' personal bibliographies	Links to information on researchers in the SICRIS system

Source: Personal bibliographies and: SICRIS

Upload image

Shelf entry

Adding material to shelf was successful.

Adding material to shelf failed.

It was not necessary to add the material to the shelf.

Permalink

E-mail

Impact factor

Select the library membership card:

DRS, in which the journal is indexed

Citations

Theme